Table 3. Prognostic factors that influence the overall survival.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Sex (Female) | 1.706 (0.904–3.215) | 0.099 | ||
| Age (≥ 60) | 1.919 (1.048–3.508) | 0.035 | 1.417 (0.752–2.670) | 0.281 |
| ECOG PS (1) | 1.161 (0.637–2.118) | 0.624 | ||
| AJCC stage (II) | 0.582 (0.169–2.009) | 0.392 | ||
| AJCC stage (III) | 0.720 (0.253–2.047) | 0.537 | ||
| Hepatitis (B) | 0.957 (0.516–1.776) | 0.892 | ||
| Liver cirrhosis (presence) | 2.557 (1.254–5.208) | 0.010 | 2.065 (1.006–4.240) | 0.048* |
| PVTT (presence) | 1.438 (0.798–2.597) | 0.226 | ||
| AFP (≥ 400) | 3.597 (1.824–7.092) | < 0.001 | 3.605 (1.791–7.258) | < 0.001* |
| Pretreatment CP class (B) | 1.538 (0.684–3.460) | 0.297 | ||
| GTV (≥ 214 cm3) | 0.834 (0.432–1.652) | 0.605 | ||
| Previous chemotherapy (presence) | 0.568 (0.279–1.155) | 0.118 | ||
| prNLR (≥ 2.1) | 2.941 (1.404–6.134) | 0.004 | 2.474 (1.133–5.402) | 0.023* |
Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; AJCC, American Joint Committee on Cancer; PVTT, portal vein tumor thrombosis; AFP, alpha-fetoprotein; CP, Child-Pugh; GTV, gross tumor volume; prNLR, pre-radiotherapy neutrophil-to-lymphocyte ratio.
*Statistically significant.